The results demonstrated that SDT combined with anti-PD-L1 significantly inhibited distal tumor growth and increased infiltration of CD4+ and CD8+ T cells, suggesting that this strategy could activate systemic immune responses and improve checkpoint inhibitor efficacy. The gene discussed is CD8A; the disease is neoplasm.